

EMP Proje Danışmanlık LTD.ŞTİ

Overview

The fully automated urine sediment analyzer developed by EMP is a domestically produced laboratory device that works with flowcell technology and artificial intelligence-supported analysis infrastructure. It offers high precision, speed and automation advantages for the needs of public and private healthcare organizations.



The Biggest Gap in the Market

The urine sediment analyzers market in Turkey is heavily dependent on imports. This is characterized by high hardware costs, foreign exchange risk and limited accessibility.



EMP's Innovative Response

The domestic analyzer developed by EMP is a CE compliant alternative that offers the advantage of low cost, fast availability and technical support.



Why EMP?

Thanks to its domestic production, Alassisted analysis, full automation, LIS integration and flexible software architecture, our device is distinguished from its competitors in terms of clinical accuracy, ease of use and cost advantage.



Team

Project Coordinator: Metin Polat

R&D Leader: Murat Polat

Mechatronics Engineer: Muhammed Ali

Soydaş

Mechatronics Engineer: Yunus Emre

Mert

Entrepreneur Contact Information:

Email: metin@emparge.com.tr

Section 2 Phone number: 0533 170 74 43



Target Market and Growth Potential

The lack of domestic products, import costs and the transition to artificial intelligence put our device in an advantageous position in the market. With its "Domestic Goods Certificate" and CE compliance, it has the potential to be prioritized in public procurement.



Current Status

The prototype design has been completed and work on flowcell integration and artificial intelligence development is ongoing. The device is configured according to CE compliant criteria.



Business Model

In addition to direct sales to public and private hospitals, our device will be offered to the market through a regional dealership network and DMO.



Future Plans:

Short Term: Completion of Flowcell integration, accuracy optimization of artificial intelligence algorithms, initiation of CE certification process, transition to platform structure interoperable with LIS and HIS systems, field tests in pilot laboratories, preparation for DMO and public tender applications

Long Term: Development of artificial intelligence model with collected data, continuous data training to increase clinical accuracy, expansion to foreign markets, development of optional strip module